Open-label, Single-arm Study to Assess the Pharmacokinetics, Safety, and Tolerability of a Single Subcutaneous Dose of Icatibant in Healthy Japanese Volunteers

Phase 1

Completed

Conditions: Hereditary Angioedema (HAE)

Interventions: Drug: Icatibant (30 mg)

Registration Number: NCT02045264

Lead Sponsor: Shire

Brief Summary: This is a single-dose study to evaluate the pharmacokinetics, safety, and tolerability of icatibant administered to adult Japanese subjects.

Detailed Description: Icatibant has been studied for the treatment of acute attacks of hereditary angioedema (HAE), an autosomal dominant disorder characterized by recurrent and self-limiting episodes of edema of the skin, larynx, and gastrointestinal tract. The most serious manifestation of an HAE attack is laryngeal edema, causing obstruction of the upper airways that may lead to death by asphyxiation if undiagnosed and/or untreated.

Icatibant has been approved in over 40 countries around the world including the United States (US) and Europe for the treatment of acute attacks of hereditary angioedema (HAE) in adults. This study is being conducted to evaluate the safety and tolerability of icatibant in a Japanese population and to evaluate whether race/ethnicity impacts the pharmacokinetics of icatibant after single subcutaneous injection.

This is an open-label, single-arm study that will enroll at least 12 Japanese subjects (in order to have 12 subjects complete the study), age 18-55 years inclusive. All subjects will receive a single subcutaneous injection of 30mg icatibant. The study will be conducted at 1 site in the US. The study will consist of a Screening Period, a Treatment Period, and a Follow-Up Period.

Recruitment & Eligibility

Status: COMPLETED

Sex: All

Target Recruitment: 12

Inclusion Criteria

Healthy male and female volunteers, 18 to 55 years of age, inclusive; healthy status defined as absence of clinically significant findings in medical history or screening assessments
Japanese; defined as born in Japan, lived outside of Japan for no more than 10 years, and having Japanese parents and Japanese maternal and paternal grandparents
Body mass index of 18 to 28 kg/m2, inclusive

Exclusion Criteria

History of, or current, clinically significant disease and/or abnormalities
Smoking habit in excess of 5 cigarettes per day or the equivalent within 30 days of Day 1 or inability to refrain from smoking during the study confinement period
Subject has current abnormal thyroid function, as defined as abnormal screening thyroid stimulating hormone (TSH) and free thyroxine (T4). Treatment with a stable dose of thyroid medication for at least 12 weeks is permitted
History of drug allergy or other allergy that, in the opinion of the investigator, contraindicates participation
Male subjects who consume more than 21 units of alcohol per week or 3 units per day. Female subjects who consume more than 14 units of alcohol per week or 2 units per day. (1 alcohol unit =1 beer or =1 wine (5oz/150mL) or =1 liquor (1.5oz/40mL) or =0.75oz alcohol)
Routine consumption of more than 2 units of caffeine per day or subjects who experience caffeine withdrawal headaches. (1 caffeine unit is contained in the following items: one 6oz (180mL) cup of coffee, two 12oz (360mL) cans of cola, one 12oz cup of tea, three 1oz (85g) chocolate bars. Decaffeinated coffee, tea, or cola are not considered to contain caffeine)
Current use of any medication (including over-the-counter, herbal, or homeopathic preparations) with the exception of female hormonal replacement therapy or hormonal contraceptives. Occasional use of over-the-counter doses of ibuprofen or acetaminophen for minor self-limited pain (eg, headaches) is also acceptable. Current use is defined as use within 7 days of the first dose of investigational product\
Pregnant or lactating females

Study & Design

Study Type: INTERVENTIONAL

Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Icatibant (30 mg)	Icatibant (30 mg)	30mg dose of icatibant is administered as a single subcutaneous injection in the abdominal area

Primary Outcome Measures

Name	Time	Method
Time to Peak Plasma Concentration (Tmax) of Icatibant and Metabolites	Over 48 hours post-dose	Tmax is the time after administration of a drug when the maximum plasma concentration in the body is reached.
Drug Concentration Half-Life (T1/2) of Icatibant and Metabolites	Over 48 hours post-dose	The time it takes for the blood plasma concentration of a substance to halve.
Area Under the Plasma Concentration-time Curve (AUC) From Time Zero to Infinity (AUCinf) of Icatibant and Metabolites	Over 48 hours post-dose	AUCinf is the area under the plasma concentration versus time curve extrapolated from time 0 to infinity, calculated using the observed value of the last non-zero concentration. AUC can be used as a measure of drug exposure. It is derived from drug concentration and time so it gives a measure how much and how long a drug stays in a body.
Total Body Clearance (CL/F) of Icatibant	Over 48 hours post-dose	The rate at which a drug is removed from the body.
Area Under the Plasma Concentration-Time Curve From Time Zero to the Time of the Last Quantifiable Concentration (AUC0-t) of Icatibant and Metabolites	Over 48 hours post-dose	AUC0-t is the area under the plasma concentration versus time curve extrapolated from time 0 to to the last quantifiable concentration. AUC can be used as a measure of drug exposure. It is derived from drug concentration and time so it gives a measure how much and how long a drug stays in a body.
Peak Plasma Concentration (Cmax) of Icatibant and Metabolites	Over 48 hours post-dose	Cmax is a term that refers to the maximum (or peak) concentration that a drug achieves in the body after the drug has been administrated.

Secondary Outcome Measures

Name	Time	Method
The Total Number of Treatment-Emergent Adverse Events	TEAEs were collected after the single dose of icatibant until follow up, 5-7 days after icatibant administration	Treatment-emergent adverse events (TEAEs) were those that started after the single dose of icatibant.
The Percentage of Subjects With Any Injection Site Reactions.	Over 48 hours post-dose
Safety Evaluation Measured by Percentage of Subjects With Not Clinically Significant Abnormalities in ECG Results	Over 48 hours post-dose
Change From Baseline in Diastolic Blood Pressure	Over 48 hours post-dose
Change From Baseline in Systolic Blood Pressure	Over 48 hours post-dose
Change From Baseline in Pulse Rate	Over 48 hours post-dose